Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging Therapies

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Adam Brufsky, MD, PhD; Kamel Abou Hussein, MD; and Priyanka Sharma, MD, FASCO, discuss personalizing care in early-stage triple-negative breast cancer (TNBC) and the evolving first-line strategies and their implications for downstream sequencing in metastatic TNBC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Integrate actionable biomarkers with tumor biology and patient-specific factors to guide individualized therapeutic decisions in early and advanced TNBC
• Assess key differences in safety profiles between current and emerging systemic therapies and implications for management of treatment-related adverse events in patients with TNBC
• Describe unique features of emerging treatments and ongoing studies to enhance clinical decision-making regarding novel agents and combination regimens in the management of TNBC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Chair:

Adam Brufsky, MD, PhD

Professor of Medicine
Co-Director, Cancer Therapeutics Program
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Agendia, AstraZeneca, Bria-Cell, Celcuity, Daiichi Sankyo, Genentech/Roche, Gilead, Lilly, Merck, Myriad, Novartis, Pfizer, Puma, Sanofi; Ownership interests in privately held companies: Celcuity

Faculty:

Kamel Abou Hussein, MD

Assistant Professor of Medicine
Cooper Medical School of Rowan University
Co-Director, Janet Knowles Breast Cancer Center
Cooper University Health Care
Camden, NJ

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca; Speakers Bureau: Lilly

Priyanka Sharma, MD, FASCO

Frank B. Tyler Professor in Cancer Research
Division of Medical Oncology, Department of Internal Medicine
University of Kansas Medical Center
Co-Program Leader Drug Discovery, Delivery, and Experimental Therapeutics program
University of Kansas Cancer Center
Kansas City, KS

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Menarini Stemline, Novartis, Pfizer; Grant/Research Funding: Novartis, Gilead (funding to the institution); Royalty or Patent Benefits: UpToDate

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including panel discussions on early-stage and metastatic TNBC, go to https://www.gotoper.com/mbcc26tnbc-activity.

Release Date

April 24, 2026

Expiration Date

April 24, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.